fbpx

Recently Diagnosed or Relapsed? Stop Looking For a Miracle Cure, and Use Evidence-Based Therapies To Enhance Your Treatment and Prolong Your Remission

Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.

Click the orange button to the right to learn more about what you can start doing today.

Myeloma Therapy- Bisphosphonates, Osteoporosis, Heart Damage?

Share Button

“The relative risk (RR) of heart failure was significantly increased in users of bisphophonates…Similarly, the risk for atrial fibrillation and other arrhythmias as well as heart failure, was significantly higher in patients treated with zoledronic acid compared with in untreated patients…”

The two studies linked and excerpted below offer a sort of circular argument for the MM patient who also take bisphosphonates to strengthen their bones. Many chemotherapy regimens cause heart damage setting up the MM patient for more damage to their heart by bisphosphonate therapy.

Let me explain.

Osteoporosis, osteopenia and bone damage are a common symptom of my cancer, multiple myeloma. Both osteoporosis and osteopenia are a common health problem of the elderly.

Many of the chemotherapy regimens prescribed for patients with multiple myeloma are cardiotoxic and can cause short, long-term and late stage cardiovascular disease aka heart damage.

Cardiovascular disease is common in the elderly and is the number one cause of death in the United Stages today. Cancer is a close number two cause of death.

According to the research linked and excerpted below, the standard-of-care for osteoporosis, osteopenia and bone damage are therapies that can cause cardiovascular disease.

To put this in real terms (at least for me), when I was a newly diagnosed multiple myeloma patient in 1994, I was prescribed high dose bisphosphonate therapy as a part of my standard-of-care MM therapy plan.

I developed chronic atrial fibrillation (AFib) in late 2010. I was diagnosed with chemotherapy-induced Cardiomyopathy (CIC) shortly thereafter.

I’ll never know if my CIC was caused by the cardiotoxic chemotherapy regimens

  • melphalan, 
  • vincristine, 
  • busulphan
  • cytoxan or
  • bisphosphonate therapy.

I underwent all of these therapies. All of these therapies are approved by the FDA as being “safe and effective.” I had an echocardiogram before my autologous stem cell transplant. Dr. Ephron gave me the “all-clear.”

In September of 1997 my oncologist told me that she could do nothing more for me. Two months later I began a non-conventional therapy that is not approved by the FDA. I achieved complete remission from my cancer in early 1999 where I remain today.

I manage my chemotherapy-induced Cardiomyopathy with evidence-based, non-conventional, non-toxic nutrition and supplementation such as CoQ10, C0cao, Taurine, others. These therapies have not been approved by the FDA for safety and efficacy.

If you have been diagnosed with multiple myeloma or have just been diagnosed with osteoporosis or osteopenia, I guess you have to choose between therapies approved by the FDA for safety and efficacy of evidence-based non-conventional, non-toxic therapies.

If you’d like to learn more about non-toxic heart health therapies, scroll down the page, post a question or comment and I will reply to you ASAP.

Hang in there,

David Emerson

  • MM Survivor
  • MM Cancer Coach
  • Director PeopleBeatingCancer

Recommended Reading:


Heart failure in patients treated with bisphosphonates

Results: The mean follow-up times were 2.8, 5.5 and 4.9 years for alendronate-, etidronate- and raloxifene-treated patients, respectively. The absolute risk of heart failure was 4.4% in the exposed group and 3.7% in the control group (P < 0.01).

The relative risk (RR) of heart failure was significantly increased in users of bisphophonates: crude RR 1.71 adjusted hazard ratio (HR) 1.41…

When the two most commonly used bisphosphonates, alendronate and etidronate, were analysed separately, significant trends in the risk of heart failure were observed across refill compliance strata.

The risk of heart failure increased significantly with increasing refill compliance for etidronate, whereas it decreased for alendronate.

Conclusions: Bisphosphonate users were at increased risk of heart failure compared to age- and gender-matched control subjects. However, users of alendronate showed a dose-dependent reduction in this risk, suggesting that alendronate may reduce the risk of heart failure.

Cardiovascular Event Risks With Zoledronic Acid vs Oral Bisphosphonates

“Patients treated with zoledronic acid had a higher risk for heart failure, among other cardiovascular conditions, according to a study presented at the American Society for Bone and Mineral Research (ASBMR) 2017 Annual Meeting held September 8-11 in Denver, Colorado.1

Researchers from the University of Southern Denmark in Odense analyzed data from a 5-year propensity score matched cohort from 2 national health registries to determine the incidence of safety-related outcomes in patients treated with zoledronic acid (21,520 person-years) vs patients treated with oral bisphosphonates (63,020 person-years) or untreated patients (63,880 person-years).

During a median period of 2.4 years, the researchers observed a higher risk for heart failure in patients treated with zoledronic acid compared with patients treated with oral bisphosphonates.

Similarly, the risk for atrial fibrillation and other arrhythmias as well as heart failure, was significantly higher in patients treated with zoledronic acid compared with in untreated patients…

The researchers could not definitively conclude that the higher rates of cardiovascular events were related to a drug effect, a difference in risk at baseline, or both, because of the study’s observational nature.

“It is possible that [zoledronic acid] was targeted to a frailer subset of patients than [oral bisphosphonates],” they wrote. “[Al]though propensity score matching and confounder adjustment was employed to reduce the influence of confounding, information on confounders such as smoking, alcohol, exercise, and [body mass index] is not available in national registries.”

Strontium ranelate

“On 13 May 2013, Servier released a Direct Healthcare Professional Communication which stated that new restrictions for the use of strontium ranelate are now in place, as randomised trials have shown an increased risk of myocardial infarction

…The European Pharmacovigilance Risk Assessment Committee (PRAC) recommends restriction in the use of strontium ranelate, based on a routine benefit-risk assessment of the medicine, which included data showing an increased risk of heart problems, including heart attacks.[3]

On 21 February 2014 the European Medicine Agency recommended that strontium ranelate remain available with restrictions relative to patients with existing heart disease.[4]”

Bisphosphonates and cardiovascular risk in elderly patients with previous cardiovascular disease: a population-based nested case-control study in Italy

“Background: In a globally aging population, chronic conditions with a high impact on healthcare costs and quality of life, such as osteoporosis and associated fractures, are a matter of concern.

For osteoporosis, several drug treatments are available, but evidence on adverse cardiovascular and cerebrovascular (CCV) events, and in particular the risk of atrial fibrillation (AF), related to anti-osteoporotic drug use is inconclusive.

The objective of this study was to evaluate the association between the use of bisphosphonates (BPs), strontium ranelate (SR), and other anti-osteoporosis drugs and the risk of AF and CCV events in a large cohort of patients affected by CCV diseases…

Leave a Comment:

1 comment
Christine Gerez says a few months ago

David is the bone health supplement guide available online or can you send to me please?

Reply
Add Your Reply